Alfa Wassermann Proteomic Technologies, LLC, Partners with Alexander Capital Corporation to Provide Customer Leasing Opportunities

Alfa Wassermann Proteomic Technologies, LLC, (AWPT), a division of Alfa Wassermann, Inc., announced today an agreement with Alexander Capital Corporation (ACC), a privately held leasing company, to make flexible leasing options available for customers interested in AWPT products. This agreement will give research, drug development, and other organizations easy and affordable access to AWPT technology.

“In seeking a financial solution for researchers interested in our products, particularly the AW PROMATIX 1000™, were pleased to discover Alexander Capital Corporation’s ability to offer competitive and creative financing packages,” said Dino DiCamillo, President of AWPT. “It will give our clients greater flexibility and freedom in acquiring our product line.”

Researchers are interested in using the AW PROMATIX 1000™ for cellular fractionation because it automatically separates, accumulates, and enriches organelles using a novel preparative continuous-flow ultracentrifugation. Gaining access to intact and functional organelles obtained, will aid research in cell transport, drug metabolism, metabolic disorders, ADME and toxicology, and proteomics.

“Our goal is to provide attractive financing solutions tailored to our vendor partners' products and markets,” said ACC Executive Vice President, Dave Dodge. “As a global leader in the life science instrumentation market, we are extremely delighted to add Alfa Wassermann Proteomic Technologies to our list of valued vendor clients. And with our Master Lease agreement in place with numerous major universities, hospitals, and pharmaceutical companies, we are able to quickly facilitate the acquisition of AWPT instruments in many major research centers around the country.”